Veru Inc. (VERU)
VERU Stock Price Chart
Explore Veru Inc. interactive price chart. Choose custom timeframes to analyze VERU price movements and trends.
VERU Company Profile
Discover essential business fundamentals and corporate details for Veru Inc. (VERU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Feb 1999
Employees
210.00
Website
https://www.verupharma.comCEO
Mitchell S. Steiner F.A.C.S.,
Description
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
VERU Financial Timeline
Browse a chronological timeline of Veru Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 15 Dec 2025
EPS estimate is -$0.49.
Earnings released on 12 Aug 2025
EPS came in at -$0.50 surpassing the estimated -$0.55 by +9.09%.
Stock split effective on 11 Aug 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%.
Earnings released on 13 Feb 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 16 Dec 2024
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $6.66M , beating expectations by +86.98%.
Earnings released on 8 Aug 2024
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $3.95M , beating expectations by +11.06%.
Earnings released on 8 May 2024
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $4.14M , beating expectations by +37.84%.
Earnings released on 1 Apr 2024
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $2.14M , missing expectations by -58.83%.
Earnings released on 8 Dec 2023
EPS came in at -$0.16 surpassing the estimated -$0.20 by +20.00%, while revenue for the quarter reached $3.86M , missing expectations by -2.23%.
Earnings released on 10 Aug 2023
EPS came in at -$0.13 surpassing the estimated -$0.20 by +35.00%, while revenue for the quarter reached $3.34M , missing expectations by -15.41%.
Earnings released on 11 May 2023
EPS came in at -$0.44 falling short of the estimated -$0.33 by -33.33%, while revenue for the quarter reached $6.59M , beating expectations by +52.45%.
Earnings released on 9 Feb 2023
EPS came in at -$0.46 falling short of the estimated -$0.38 by -21.05%, while revenue for the quarter reached $2.51M , missing expectations by -50.50%.
Earnings released on 5 Dec 2022
EPS came in at -$0.51 falling short of the estimated -$0.29 by -75.86%, while revenue for the quarter reached $2.59M , missing expectations by -77.59%.
Earnings released on 11 Aug 2022
EPS came in at -$0.28 falling short of the estimated -$0.18 by -55.56%, while revenue for the quarter reached $9.60M , missing expectations by -42.39%.
Earnings released on 12 May 2022
EPS came in at -$0.18 falling short of the estimated -$0.16 by -12.50%, while revenue for the quarter reached $13.03M , beating expectations by +6.72%.
Earnings released on 9 Feb 2022
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%, while revenue for the quarter reached $14.14M , beating expectations by +2.12%.
Earnings released on 2 Dec 2021
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%, while revenue for the quarter reached $15.65M , beating expectations by +20.36%.
Earnings released on 12 Aug 2021
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $17.66M , beating expectations by +25.22%.
Earnings released on 12 May 2021
EPS came in at -$0.04 falling short of the estimated -$0.04 by -5.26%, while revenue for the quarter reached $13.34M , meeting expectations.
Earnings released on 10 Feb 2021
EPS came in at -$0.02 falling short of the estimated -$0.01 by -64.74%, while revenue for the quarter reached $14.62M , missing expectations by -80.95%.
Earnings released on 9 Dec 2020
EPS came in at -$0.01 surpassing the estimated -$0.05 by +80.00%, while revenue for the quarter reached $11.75M .
VERU Stock Performance
Access detailed VERU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.